Feb 07, 2024 / 07:30PM GMT
Yatin Suneja - Guggenheim Securities, LLC, Research Division - Senior MD & Equity Research Analyst
Okay. Good afternoon, everyone. Yatin Suneja from Guggenheim. Welcome to our 6th Annual Biotechnology Conference. Our next presenting company is Roivant. From the company, we have Chief Financial Officer Richard Pulik. Richard, why don't you give maybe a 5-minute overview of the company, maybe talk about some of the upcoming milestones, and then we'll go into the Q&A.
Richard Pulik - Roivant Sciences Ltd. - CFO
Great. Thanks so much for having us, Yatin, and for your great coverage. Look, I think it's a super exciting year for us. We have, post the Telavant deal, roughly $7 billion in cash, which makes us one of the best capitalized biotech companies out there. I think that drives a lot of optionality to do more deals. We're -- obviously, in our 10-year history, have done some pretty spectacular deals and are continuing to remain very active there.
I would say, on the back of JPMorgan, it was probably one of the most exciting years I've seen. Lots
Roivant Sciences Ltd at Guggenheim Healthcare Talks Biotechnology Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers